BEAM (Beam Therapeutics) Net Profit

Corporate emblem and logo of beamtx.com (BEAM)

Beam Therapeutics Inc. (BEAM) is developing a precision genome editing system, expanding its hematology portfolio through partnerships with industry behemoths. The company's profit trend confirms this stage, where -0.09 captures the current value of the indicator. Management's expertise in patenting ensures scientific progress; however, the lack of revenue and high R&D costs create a severe liquidity deficit.

Beam Tx (BEAM): Net Income from 07/04/2022 to 11/01/2026

Financial and market metric breakdowns for Beam Therapeutics (BEAM)

- stock value and consensus price forecast:
Market Price Beam Tx|BEAM - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Beam Tx|BEAM - Total Company Value
- book capitalization data:
Accounting Value per Share Beam Therapeutics|BEAM - Company Net Assets|Market Value to Book Value beamtx.com|BEAM - Cumulative Company Assets
- debt and liquidity details:
Aggregate Debt to Capital Beam Therapeutics Inc.|BEAM - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Beam Therapeutics Inc|BEAM - Company Aggregate Debts|Debts to Book Value Beam Tx|BEAM - Company Long-Term Debt|Company Short-Term Loans and Borrowings Beam Therapeutics|Quick Ratio beamtx.com
- net income and valuation ratios data:
BEAM - Company Net Income
Fundamental valuation:BEAM Beam Tx
Flagship merchandise of Beam Therapeutics Inc

The development efficiency of the Beam Therapeutics Inc. (BEAM) base editing platform correlates directly with R&D investment levels and the preservation of cash reserves. By analyzing the company's financial performance dynamics, investors assess the stability of operating income and the trend vector regardless of trading volumes, which allows them to determine the actual viability of the business and minimize the risks of prolonged capital depreciation.

Main competitors

Company Net Income Tempus AI (TEM)|QGEN (Qiagen N.V.) - Net Profit|Net Profit ionispharma.com|Company Net Income Repligen (RGEN)|Net Income Avidity Biosciences Inc RNA|CRISPR Therapeutics Corp - Net Income|Final Profit WGS|RARE: Net Income|sarepta.com - Profit After Payment of Taxes|TWST: Net Profit|10x Genomics Inc - Final Profit|NTLA (Intellia) - Net Profit|Company Net Income Stoke Corp STOK|Company Net Income BioLife Solutions, Inc. (BLFS)|WVE (wavelifesciences.com) - Final Profit|Net Profit MAZE (Maze Therapeutics)|Net Profit Sionna Therapeutics, Inc. SION|PRME - Company Net Income|Profit After Tax TSHA|QURE: Net Profit|Company Net Income meiragtx.com (MGTX)|Net Income RGNX|Net Profit Solid Biosciences Inc|Net Income OCGN (Ocugen Corp)|Profit After Payment of Taxes PACB|Net Profit BNTC (Benitec Biopharma Inc.)|Net Financial Result designtx.com (DSGN)|Rocket Pharmaceuticals, Inc. - Net Profit|4DMT (FDMT) - Net Income|lexeotx.com (LXEO) - Company Net Income|KRRO - Net Financial Result|Net Income EDIT|SLN: Final Profit|Net Profit PRQR|Net Financial Result codexis.com|Company Net Income Sangamo SGMO|NAUT: Company Profit|Metagenomi, Inc. - Net Profit|Precision BioSciences Inc. (DTIL) - Net Income|GBIO (generationbio.com) - Net Income|BOLD - Net Financial Result|XCUR (Exicure Inc.) - Net Profit|Company Net Income IMNN|Net Profit PHIO|MBIO - Company Net Income|Net Profit RNAZ (TransCode Therapeutics, Inc.)|Net Profit Bionano Genomics Inc. BNGO|APDN - Company Net Income|bluebird bio, Inc (BLUE) - Net Income|IPA: Net Profit|Company Profit OMGA|Company Net Income Singular Genomics|Company Profit RGLS (Regulus Therapeutics, Inc.)|Net Profit SYRS|Net Profit Telesis Bio, Inc (TBIO)|Net Profit TCON (TRACON Pharmaceuticals)|unitybiotechnology.com - Company Net Income